Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

350
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
350
Cancer Survival Analysis01:21

Cancer Survival Analysis

481
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
481

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toward a Better Paradigm for Head and Neck Cancer Treatment Applying AI (HNC-TACTIC): Protocol for an International Cohort Study of Electronic Health Records.

JMIR research protocols·2026
Same author

Peripheral immune cell subsets as potential predictors of benefit from immune checkpoint blockade therapy in small cell lung cancer.

Frontiers in immunology·2026
Same author

Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Correction: How should we interpret excessive left ventricular trabeculation? Update on controversies from the cardiac imaging perspective.

Insights into imaging·2026
Same author

Tumor B-cell infiltration in platinum-treated advanced muscle-invasive urothelial carcinoma.

Molecular oncology·2026
Same author

Integrating Genetic Variants and Expression Profiles of Pharmacogenes to Investigate Resistance to Antidepressant Treatment.

Medicina (Kaunas, Lithuania)·2026

Related Experiment Video

Updated: Oct 18, 2025

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

20.1K

Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC.

Pedro Rocha1, Didac Ramal2, Enric Ripoll2

  • 1Medical Oncology Department, Hospital del Mar, Barcelona, Spain.

JTO Clinical and Research Reports
|September 30, 2021
PubMed
Summary

Hyperprogressive disease (HPD) incidence in non-small cell lung cancer (NSCLC) is higher with immune checkpoint inhibitors. Tumor growth rate and kinetics show high concordance for HPD assessment, unlike RECIST 1.1.

Keywords:
ChemotherapyHyperprogressive diseaseImmune checkpoint inhibitorsNSCLC

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

269

Related Experiment Videos

Last Updated: Oct 18, 2025

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

20.1K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

269

Area of Science:

  • Oncology
  • Immunotherapy
  • Clinical Trial Methodology

Background:

  • Hyperprogressive disease (HPD) is a controversial complication of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC).
  • Inconsistent findings regarding HPD incidence and survival outcomes necessitate standardized assessment methods.

Purpose of the Study:

  • To compare the incidence of HPD in NSCLC patients treated with nivolumab (an ICI) versus docetaxel (chemotherapy).
  • To evaluate the concordance of three different methods for quantifying HPD: tumor growth rate (TGR), tumor growth kinetics (TGK), and RECIST 1.1.

Main Methods:

  • A cohort of 42 NSCLC patients treated with nivolumab and 37 treated with docetaxel were analyzed.
  • HPD was quantified using TGR, TGK, and RECIST 1.1 criteria.
  • HPD rates and concordance between methods were compared between treatment groups.

Main Results:

  • HPD incidence was numerically higher in the nivolumab cohort (14.3-16.7%) compared to the docetaxel cohort (8.1-13.6%).
  • TGR and TGK demonstrated high concordance (90.1%), while RECIST 1.1 showed low concordance with TGR (31.3-37.5%) and TGK.
  • No significant difference in overall survival was observed between patients with progressive disease and HPD in either group.

Conclusions:

  • TGR and TGK are reliable and concordant methods for identifying HPD in NSCLC.
  • The incidence of HPD appears higher with ICIs, warranting further investigation.
  • Standardization of HPD assessment methods is crucial for understanding its clinical significance in NSCLC.